http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
척수 경막하 출혈로 인한 하지마비 환자의 한방치료를 통한 근력 및 감각 호전 1례
오세정,임성철,이윤규,김재수,이현종,Oh, Se Jung,Lim, Seong Chul,Lee, Yun Kyu,Kim, Jae Soo,Lee, Hyun Jong 대한침구의학회 2014 대한침구의학회지 Vol.31 No.3
Objectives : The objective of this study is to report the clinical effects of Korean medical treatment for spinal subdural hematoma associated with anticoagulant drug. Methods : The patients were treated using acupuncture, electroacupuncture, herbal medication, moxibustion and physical treatment. And we checked American Spinal Injury Association scale, Spinal Cord Independence Measure Version III. Results : Motor score on the American Spinal Injury Association scale is increased 50 to 72. Sensory score on the American Spinal Injury Association scale is increased 124 to 170. Spinal Cord Independence Measure Version III is increased 18 to 26. Conclusions : This study suggest that Korean medical treatments are effective to spinal subdural hematoma patient.
액와접근법과 흉부접근법을 통한 내시경 갑상선 절제술의 임상적 고찰
성기영,오세정,백종민,이도상,김욱,박일영,원종만,Gi Young Sung,M,D,Se Jeong Oh,M,D,Jong Min Baek,M,D,Do Sang Lee,M,D,Wook Kim,M,D,Il Young Park,M,D,and Jong Man Won,M,D 대한갑상선-내분비외과학회 2004 The Koreran journal of Endocrine Surgery Vol.4 No.1
Purpose: The thyroid suregry has recently become one of the newest fields for the application of endoscopic surgery. We have performed endoscopic thyroidectomy by an anterior chest approach and an axillary approach. In this study, we evaluated these two types of endoscopic procedures with regard to efficacy and patients' complaints after surgery.Methods: Between December 2000 and March 2002, 41 patients were treated by endoscopic thyroidectomy via axillary or anterior chest approach. Each procedure was performed by one surgeon under a general anesthesia. We analysed the operating time, postoperative complications, postoperative scar, the degree of pain to assess the surgical invasiveness of each procedure.Results: Three cases treated using anterior chest approach, and 2 cases treated using axillary approach were converted to conventional thyroidectomy. The mean age of patients was 36 years in anterior chest approach group and 30 years in axillary approach group. The operation time was 238⁑60 (160∼370) minutes in anterior chest approach and 178⁑71 (100∼295) minutes in axillary approach. Postoperative complications are; 1 case of a minimal hematoma, 3 cases of minor wound infection, 3 cases of chest pain in anterior chest approach group, and 1 case of a minimal hematoma, 1 case of transient recurrent laryngeal nerve injury, 1 cases of transient swallowing difficulties in axillary approach group.Conclusion: Endoscopic (gasless and axillary approach) thyroidectomy is a safe and effective procedure. Gasless endoscopic thyroidectomy is a useful procedure for unexperienced surgeon due to safety. Endoscopic thyroidectomy by the axillary approach is a better effective procedure with good cosmetic result for a unilateral tumor especially in young women. (Korean J Endocrine Surg 2003;4:26-30)
김연희 ( Yeun Hee Kim ),오세정 ( Sae Jeong Oh ),안현영 ( Hyun Young Ahn ),길기철 ( Ki Cheol Kil ),박인양 ( In Yang Park ),이귀세라 ( Gui Se Ra Lee ),김수평 ( Soo Pyung Kim ),신종철 ( Jong Chul Shin ) 대한주산의학회 2006 Perinatology Vol.17 No.4
목적 : 신장이식수술을 받은 환자에서 생긴 임신의 결과와 이식신의 예후에 대하여 알아보고자 하였다. 방법 : 1990년 1월부터 2003년 12월까지 14년 간 신장이식수술을 받은 가임기(15~45세) 여자 환자를 대상으로 후향적으로 연구하였다. 이식수술 후 발생한 임신에 대하여 임신의 결과와 산과적 합병증 및 신생아 결과 그리고 이식신의 예후에 대하여 의무기록을 검토하였다. 결과 : 연구기간 중 총 224명의 가임기 여성이 신장이식수술을 받았으며 21명의 환자에서 34예의 임신을 경험하였다. 임신 시 평균 나이는 29.5세였으며 이식수술로부터 평균 61.9개월(범위:1~162)후 임신하였다. 임신의 결과로 생존출생 67.6% (23예) 중 13예가 조산하였으며 자연유산 8.8% (3예), 인공유산 20.5% (7예) 그리고 자궁외임신이 2.9%(1예)였다. 산모측 합병증으로 전자간증39.1%, 조기진통 43.4%, 요로감염 38.2% 그리고 임신성 당뇨 8.6%가 발생하였다. 이식수술 후 2년 미만에 임신한 9예에서 임신의 결과와 합병증이 2년 이후에 임신한 군과 통계적으로 유의한 차이를 보이지 않았다(자연유산: p=0.77, 인공유산: p=0.88, 생존출생: p=0.36). 임신 후 일시적 신기능 장애를 보인 군에서 유산율이 유의하게 증가하였으며(p=0.006), 임신 전 혈청크레아티닌이 1.4 mg/dL 이상인 경우에 조산이 증가하였다(p=0.30). 분만 후 3~6개월 후 혈청크레아티닌 농도가 임신 전에 비하여 유의하게 증가하였으나(p=0.04), 분만 후 2년 이식편 생존율이 95.2%, 이식수술 후 5년 생존율이 95.2%였다. 결론 : 이상의 결과로 이식신의 기능이 양호하다면 이식수술 후 2년 미만에 임신한 경우에 좋은 임신의 예후를 기대할 수 있다. 이식편의 분만 후 2년, 수술 후 5년 생존율이 양호하며 임신이 이식신의 장기간 생존율에 영향을 주지 않는 것을 보인다. Objective : The aim of our study was to identify graft, obstetric and maternal outcomes of pregnancies in renal transplant recipients at our center. Methods : A 14-year retrospective study between January 1990 and December 2003, 224 women 15 to 45 years of age had transplantation and were analyzed the outcomes of pregnancies, obstetric complications and graft function. Results : Thirty-four pregnancies occurred in 21 of 224 patients. The mean age at the time of conception was 29.5 years (21 to 36 years) with a mean interval of 61.9 months (one to 162 months). In the pregnancy outcome, there were the 23 live births (67.6%) included 13 preterm and 10 term deliveries, 3 spontaneous abortions (8.8%), 7 artificial abortions (20.5%) and one case of ectopic pregnancy (2.9%). Obstetric complications were; preeclampsia (39.1%), preterm labor (43.4%), urinary tract infections (38.2%) and gestational diabetes (8.6%). Nine pregnancies within 2 years of transplantation had the permissible obstetric outcomes comparing with the others after 2 years (spontaneous abortion: p=0.77, artificial abortion: p=0.88, live birth: p=0.36). In twelve pregnancies appearing renal dysfunction associated with pregnancy, the abortion rate was increased comparing the others with stable renal function (p=0.006). Pre-pregnancy serum creatinine .1.4 mg/dl was associated with increased preterm delivery, but not significant (50.0% vs 28.5%, p=0.30). In graft function, serum creatinine 3~6 postpartum was significantly increased comparing pre-pregnancy levels (p=0.04). Five cases of 7 patients with acute rejection episode associated with pregnancy conceived after 4 years of transplantation. Two-year graft survival after delivery was 95.2% (20/21) and chronic rejection and graft failure was diagnosed in one case at postpartum 14 months. Conclusion : These findings suggest that, if the graft function is stable, pregnancy within 2 years after renal transplantation might be safe. Pregnancy does not appear to have adverse effects on long term graft survival.
타목시펜 내성 유방암세포(T47D:A18/4-OHT)에서 EGFR 및 HER2 억제 효과
원용성(Yong Sung Won),주종호(Jong Ho Joo),김정수(Jeong Soo Kim),오세정(Se Jung Oh),송병주(Byung Joo Song),전해명(Hae Myung Jeon),정상설(Sang Seol Jung),박우찬(Woo Chan Park) 대한외과학회 2008 Annals of Surgical Treatment and Research(ASRT) Vol.74 No.4
Purpose: Tamoxifen has been prescribed as a very effective hormonal agent not only for the treatment of breast cancer, but also for the prevention of the disease. The development of resistance to tamoxifen is one of the most important obstacles to hormonal therapy of breast cancer. HER2 or EGFR expression has been reported to be associated with the development of tamoxifen resistance. This study was performed to evaluate the effect of HER2 and EGFR inhibition on tamoxifen resistance using tamoxifen-resistant breast cancer cells (T47D:A18/4-OHT cells). Methods: Tamoxifen-resistant T47D:A18/4-OHT cells were established by long-term treatment of 1μM 4-hydroxytamoxifen on T47D:A18 human breast cancer cells. The effect of HER2 and EGFR inhibition was investigated by the use of a cell proliferation assay with treatment of trastuzumab, a monoclonal antibody to the extracellular domain of the human HER2 receptor, and ZD1839, an ERFR tyrosine kinase inhibitor. Results: In contrast to T47D:A18 cells, T47D:A18/4-OHT cells showed estrogen-independent proliferation and partial regulation by treatment with tamoxifen. With a single treatment of trastuzumab or ZD1839, T47D:A18/4-OHT cell growth was reduced to 77.8% (P=0.15) or 74.4% (P=0.034) respectively, as compared to untreated cells. Combinational treatment with 1 nM estradiol resulted in a further reduction of T47D:A17 cell proliferation by 83.6% (P=0.002) for trastuzumab and 77.7% (P=0.047) for ZD1839, as compared to the single treatments. Conclusion: Tamoxifen resistance could be partially regulated by inhibition of HER2 or EGFR in T47D:A18/4-OHT cells, especially in combination with a low dose of estradiol. This effect may provide an important clue to overcome tamoxifen resistance in the treatment of breast cancer.